论文部分内容阅读
目的:探讨抗癫痫药托吡酯(TPM)对癫痫患儿骨代谢的影响。方法:对50例原发性癫痫患儿予口服TPM治疗,于治疗前和治疗后6个月、12个月分别测定骨密度(BMD)、骨碱性磷酸酶(BAP)、血钙(Ca)、磷(P)、碱性磷酸酶(ALP)。对照组为30例未治疗的原发性癫痫患儿,同期检测上述指标。对上述骨代谢指标进行评价。结果:托吡酯治疗前、治疗后6个月、12个月BMD、BAP、Ca、P、ALP与对照组比较差别无显著性(P>0.05)。结论:服用托吡酯(TPM)对3～12岁癫痫患儿骨代谢无影响。
Objective: To investigate the effect of antiepileptic topiramate (TPM) on bone metabolism in children with epilepsy. Methods: Fifty patients with primary epilepsy were treated with TPM orally. BMD, BAP, Ca ), Phosphorus (P), alkaline phosphatase (ALP). The control group was 30 untreated children with primary epilepsy, the same period the above indicators. The above indicators of bone metabolism were evaluated. Results: There was no significant difference in BMD, BAP, Ca, P, ALP between the two groups at 6 and 12 months after treatment with topiramate (P> 0.05). Conclusion: Topiramate (TPM) has no effect on bone metabolism in children aged 3 ~ 12 years with epilepsy.